INDACATEROL/MOMETASONE dry powder inhaler (Atectura Breezhaler®)

Clinical Indication

Maintenance treatment of asthma in adults and adolescents 12 years of age and older


Not yet reviewed

Date of classification

May 2021

Review date

May 2021


Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.